皓元医药(688131.SH)：苏信基金拟减持不超3%股份

Group 1 - The core point of the article is that Haoyuan Pharmaceutical (688131.SH) announced a plan for a shareholder to reduce its stake in the company due to funding needs [1] - The shareholder, Su Min Investment Junxin (Shanghai) Industry Upgrade and Technology Innovation Equity Investment Partnership (Limited Partnership), intends to reduce its holdings by up to 6.363 million shares [1] - The proposed reduction represents no more than 3% of the company's current total share capital [1]